**Supplementary Table 1. Treatment switch details.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Treatment switch, n (%)** | **Apremilast****n = 471** | **TNFi****n = 804** | **ILi****n = 86** |
| Treatment switched to: |  |  |  |
| Apremilast | – | 69 (23.8) | 4 (20.0) |
| Ustekinumab | 22 (19.3) | 54 (18.6) | – |
| Adalimumab | 56 (49.1) | 44 (15.2) | 6 (30.0) |
| Certolizumab | 1 (0.9) | 7 (2.4) | 2 (10.0) |
| Etanercept | 13 (11.4) | 56 (19.3) | 3 (15.0) |
| Golimumab | 1 (0.9) | 3 (1.0) | – |
| Infliximab | 1 (0.9) | 13 (4.5) | 1 (5.0) |
| Ixekizumab | 5 (4.4) | 13 (4.5) | 2 (10.0) |
| Secukinumab | 14 (12.3) | 31 (10.7) | 2 (10.0) |
| Guselkumaba | 1 (0.9) | – | – |

aGuselkumab was not captured as an index therapy, but was included as a treatment to which patients could switch following index therapy.

ILi: interleukin inhibitors; TNFi: tumor necrosis factor inhibitors.